欧州医薬品庁(EMA)が進行腎細胞がんの一次治療におけるニボルマブ+イピリムマブ併用療法の承認について、否定的見解【ESMO】

On 26 July 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of a change to the marketing authorisations for the medicinal products nivolumab (Opdivo) and ipilimumab (Yervoy). Intended change concerned adding the use of both medicines in combination for first-line treatment of advanced renal cell carcinoma.

 

コメント

Leave a comment

Your email address will not be published.


*